[{"id":40291,"versionId":15,"title":"September 2023","type":2,"subType":null,"childSubType":"","date":"9/25/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-september-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-september-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Donislecel-jujn (Lantidra)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39570,"versionId":15,"title":"August 2023","type":2,"subType":null,"childSubType":"","date":"8/28/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-august-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-august-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for (Somatrogon-ghla) Ngenla\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Epcoritamab-bysp (Epkinly)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Glofitamab-gxbm (Columvi)\u003c/li\u003e\n\u003cli\u003eReminder: Radiation Oncology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39510,"versionId":15,"title":"July 2023","type":2,"subType":null,"childSubType":"","date":"7/31/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-july-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-july-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Established for Risankizumab-rzaa (Skyrizi\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)\u003c/li\u003e\n\u003cli\u003eDiagnosis and Treatment of Obstructive Sleep Apnea in Adults\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39405,"versionId":15,"title":"June 2023","type":2,"subType":null,"childSubType":"","date":"6/26/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-june-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-june-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Established for Tofersen (Qalsody)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Delandistrogene moxeparvovec\u003c/li\u003e\n\u003cli\u003eNew Guidelines for Assisted Reproductive Technology\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39343,"versionId":15,"title":"May 2023","type":2,"subType":null,"childSubType":"","date":"5/26/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-may-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-may-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Cardiology \u0026amp; Radiology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Altuviiio\u003csup\u003e\u003cspan\u003eTM\u003c/span\u003e\u003c/sup\u003e\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Syfovre\u003c/li\u003e\n\u003cli\u003eCriteria for surgical fundoplication added to Medical Policy S-145 Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39257,"versionId":15,"title":"April 2023","type":2,"subType":null,"childSubType":"","date":"4/24/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-april-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-april-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eGuidelines Revised for Intravenous Anesthetics for Off-Label Indications\u003c/li\u003e\n\u003cli\u003eInjectable Drugs Added to Site of Care\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":39167,"versionId":15,"title":"March 2023","type":2,"subType":null,"childSubType":"","date":"3/27/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-march-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-march-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003ePolicy Criteria Revised for Sutimlimab-jome (Enjaymo)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Teplizumab-mzwv (Tzield)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Nadofaragene firadenovec-vncg (Adstiladrin)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Mosunetuzumab-axgb (Lunsumio)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Ublituximab-xiiy (Briumvi)\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":38289,"versionId":15,"title":"January 2023","type":2,"subType":null,"childSubType":"","date":"1/30/2023","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-january-2023.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-january-2023.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eHepatobiliary System Imaging\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37962,"versionId":15,"title":"December 2022","type":2,"subType":null,"childSubType":"","date":"12/22/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-december-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-december-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revision for Obesity\u003c/li\u003e\n\u003cli\u003ePolicy Established for Tremelimumab (Imjudo)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Teclistamab-cqyv (Tecvayli)\u003c/li\u003e\n\u003cli\u003eReminder: Radiology/Cardiology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37844,"versionId":15,"title":"November 2022","type":2,"subType":null,"childSubType":"","date":"11/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-november-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-november-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-adcd (Vegzelma)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Eflapegrastim-xnst (Rolvedon)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37706,"versionId":15,"title":"October 2022","type":2,"subType":null,"childSubType":"","date":"10/31/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-october-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-october-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Pegfilgrastim-pbbk (Fylnetra\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for ranibizumab-eqrn (Cimerli)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Betibeglogene autotemcel (Zynteglo)\u003c/li\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37591,"versionId":15,"title":"September 2022","type":2,"subType":null,"childSubType":"","date":"9/26/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-september-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-september-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Leuprolide Mesylate (Camcevi\u003csup\u003eTM\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Filgrastim\u003c/li\u003e\n\u003cli\u003ePolicy Established for Risankizumab-rzaa (Skyrizi\u003csup\u003e\u0026reg;\u003c/sup\u003e)\u003c/li\u003e\n\u003cli\u003eReauthorization Criteria Established for Crizanlizumab-tmca (Adakveo)\u003c/li\u003e\n\u003cli\u003eDiagnosis Codes Revised for Medical Policy Z-1, Ultraviolet Light Therapies\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37508,"versionId":15,"title":"August 2022","type":2,"subType":null,"childSubType":"","date":"8/29/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-august-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-august-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Omalizumab (Xolair)\u003c/li\u003e\n\u003cli\u003eCriteria Established for Dexamethasone Punctum Insert (Dextenza)\u003c/li\u003e\n\u003cli\u003eCriteria revised for Medical Policy M-13, Intraoperative Neurophysiologic Monitoring\u003c/li\u003e\n\u003cli\u003eObstructive Sleep Apnea Publication Delayed\u003c/li\u003e\n\u003cli\u003eFacility Guidelines Added\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":37414,"versionId":15,"title":"July 2022","type":2,"subType":null,"childSubType":"","date":"7/25/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-july-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-july-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Belimumab (Benlysta)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Abatacept (Orencia)\u003c/li\u003e\n\u003cli\u003eCriteria Established for Vutrisiran (Amvuttra)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Intraepidermal Nerve Fiber Density Testing\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Deep Brain Stimulation\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36714,"versionId":15,"title":"June 2022","type":2,"subType":null,"childSubType":"","date":"6/24/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-june-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-june-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003cli\u003eREMINDER: Spine Surgery Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eDiagnosis Codes Removed from Routine Foot Care\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36689,"versionId":15,"title":"May 2022","type":2,"subType":null,"childSubType":"","date":"5/27/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-may-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-may-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdated Criteria for Wearable Cardioverter-Defibrillator\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-maly (Alymsys)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Nivolumab and Relatlimab-rmbw (Opdualag)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Asparaginase Erwinia Chrysanthemi (Rylaze)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Posterior Tibial Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eAnd more ...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36619,"versionId":15,"title":"April 2022","type":2,"subType":null,"childSubType":"","date":"4/25/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-april-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-april-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eUpdate: Cardiology Coverage Guideline Updated\u003c/li\u003e\n\u003cli\u003eReminder: Musculoskeletal Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Discography\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Tildrakizumab-asmn (Ilumya)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Treatment of Hereditary Amyloidosis\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36530,"versionId":15,"title":"March 2022","type":2,"subType":null,"childSubType":"","date":"3/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-march-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-march-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Laboratory Management Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Intra-Articular Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Pharmacologic Treatment of Pulmonary Arterial Hypertension\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Pegloticase (Krystexxa)\u003c/li\u003e\n\u003cli\u003eCriteria Established for ranibizumab (Susvimo), ranibizumab-nuna (Byooviz), and faricimab-svoa (Vabysmo)\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36480,"versionId":15,"title":"February 2022","type":2,"subType":null,"childSubType":"","date":"2/28/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xde-mpu-feb-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/de-mpu-feb-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Radiation Oncology Coverage Guideline Update\u003c/li\u003e\n\u003cli\u003ePolicy Criteria Established for Tezepelumab-ekko\u003c/li\u003e\n\u003cli\u003ePolicy Established for Tisotumab vendotin-tftv (Tivdak)\u003c/li\u003e\n\u003cli\u003ePolicy Established for Efgartigmod alfa-fcab (Vyvgart)\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Prophylactic Mastectomy\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36381,"versionId":15,"title":"January 2022","type":2,"subType":null,"childSubType":"","date":"1/31/2022","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-jan-2022.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-jan-2022.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eBiosimilar Preferred Product Established for Rituximab\u003c/li\u003e\n\u003cli\u003eGuidelines Established for Avalglucosidase alfa-ngpt (Nexviazyme)\u003c/li\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Pegfilgrastim\u003c/li\u003e\n\u003cli\u003eGuidelines Established for Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Brentuximab Vedotin (Adcetris)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Parathyroid Hormone (Natpara)\u003c/li\u003e\n\u003cli\u003eAnd more...\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36242,"versionId":15,"title":"December 2021","type":2,"subType":null,"childSubType":"","date":"12/27/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-dec-2021.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-de-dec-2021.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revision for Obesity\u003c/li\u003e\n\u003cli\u003eInjectable Drug Added to Site of Care\u003c/li\u003e\n\u003cli\u003ePreferred Products Changed for Infliximab\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Fecal Microbiota Transplantation\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36196,"versionId":15,"title":"November 2021","type":2,"subType":null,"childSubType":"","date":"11/29/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-nov-2021-de.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-2021-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Wireless Capsule Endoscopy as a Diagnostic Technique in Disorders of the Small Bowel, Esophagus, and Colon\u003c/li\u003e\n\u003cli\u003eUPDATE: Oncology Imaging Guidelines\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Ipilimumab (Yervoy)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Disease\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":36062,"versionId":15,"title":"October 2021","type":2,"subType":null,"childSubType":"","date":"10/25/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-oct-2021-de.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-2021-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Arthrex Bovine Collagen\u003c/li\u003e\n\u003cli\u003eCriteria Revision for Non-spinal Bone Growth Stimulation\u003c/li\u003e\n\u003cli\u003ePolicy Established for Amivantamab-vmjw (Rybrevant)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":32273,"versionId":15,"title":"September 2021","type":2,"subType":null,"childSubType":"","date":"9/27/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-sept-2021-de.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-2021-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Laboratory Management Coverage Guidelines\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Fulvestrant (Faslodex)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":31657,"versionId":15,"title":"August 2021","type":2,"subType":null,"childSubType":"","date":"8/30/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-august-2021.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/august-2021-mpu-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Irinotecan (Camptosar)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Panitumumab (Vectibix)\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Aqueous Shunts and Stents for Glaucoma\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Posterior Tibial Nerve Stimulation\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":31142,"versionId":15,"title":"July 2021","type":2,"subType":null,"childSubType":"","date":"7/26/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-july-2021-de.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-2021-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Radiation Oncology Coverage Guidelines\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":28828,"versionId":15,"title":"June 2021","type":2,"subType":"0","childSubType":"","date":"6/25/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-june-2021.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-2021-de.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Melphalan Flufenamide (Pepaxto)\u003c/li\u003e\n\u003cli\u003eREMINDER: Cardiology \u0026amp; Radiology Imaging Coverage Guidelines\u003c/li\u003e\n\u003cli\u003eOncology Compendia Guidelines\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":28263,"versionId":15,"title":"May 2021","type":2,"subType":"0","childSubType":"","date":"5/28/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-may-2021-debcbs.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-2021-debcbs.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Radiation Therapy Coverage Guidelines\u003c/li\u003e\n\u003cli\u003eRevised Coverage for Private Duty Nursing\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":28164,"versionId":15,"title":"April 2021","type":2,"subType":"0","childSubType":"","date":"4/26/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-april-2021-de.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/April DELAWARE FINAL.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eBiosimilar Preferred Products Established for Bevacizumab, Rituximab, and Trastuzumab\u003c/li\u003e\n\u003cli\u003eReminder: Labratory Management Clinical Guidelines\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Rituximab (Rituxan), Rituximab Biosimilars, and Rituximab and Hyaluronidase Human (Rituxan Hycela)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Pheresis Therapy\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":28067,"versionId":15,"title":"March 2021","type":2,"subType":"0","childSubType":"","date":"3/29/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xMarch-DE.jpg","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/March-DELAWARE-FINAL.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoding Updated for Q-4 Private Duty Nursing\u003c/li\u003e\n\u003cli\u003eInjectable Drugs Added to Site of Care\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25892,"versionId":15,"title":"February 2021","type":2,"subType":"0","childSubType":"","date":"2/22/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hbs/NewsletterNotices/MPU/2xmpu-feb21.jpg","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-21.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003eCoverage Guidelines Established for Rituximab-arrx (Riabni)\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25817,"versionId":15,"title":"January 2021","type":2,"subType":"0","childSubType":"","date":"1/1/2021","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-de-jan2021.png","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-21.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Agalsidase Beta (Fabrazyme)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Lumasiran (Oxlumo)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Brexanolone (Zulresso)\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25729,"versionId":15,"title":"December 2020","type":2,"subType":"0","childSubType":"","date":"12/28/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-dec20.jpg","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Chemodenervation \u0026ndash; Botulinum Toxin\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Human Growth Hormone\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Electronystagmography (ENG) and Videonystagmography (VNG) Services\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":25327,"versionId":15,"title":"November 2020","type":2,"subType":"0","childSubType":"","date":"11/25/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-nov20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Pemetrexed (Alimta, Pemfexy)\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bevacizumab (Avastin) and Bevacizumab Biosimilars\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Programmed Death Receptor (PD-1)/ Programmed Death-Ligand (PD-L1) Blocking Antibodies\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003c/p\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":24636,"versionId":15,"title":"October 2020","type":2,"subType":"0","childSubType":"","date":"10/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-oct20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bendamustine (Treanda, Bendeka, Belrapzo)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Brexucabtagene Autoleucel (Tecartus)\u003c/li\u003e\n\u003cli\u003eUpdated Criteria for Tumor Treatment Fields\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23930,"versionId":15,"title":"September 2020","type":2,"subType":"0","childSubType":"","date":"9/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-sept20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eClinical Criteria Revised for Autonomic Nervous System Function Testing\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Private Duty Nursing\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23559,"versionId":15,"title":"August 2020","type":2,"subType":"0","childSubType":"","date":"8/31/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-aug20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-aug-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Pegfilgrastim-apgf (Nyvepria)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Elosulfase alfa (Vimizim)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Daunorubicin and Cytarabine Liposomal (Vyxeos)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":23113,"versionId":15,"title":"July 2020","type":2,"subType":"0","childSubType":"","date":"7/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-july20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Leuprolide Acetate (Fensolvi)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Sacituzumab Govitecan-hziy (Trodelvy)\u003c/li\u003e\n\u003cli\u003eRevised Coverage Criteria for Electroconvulsive Therapy\u003c/li\u003e\n\u003cli\u003eREMINDER: Cardiology \u0026amp; Radiology Imaging Clinical Guidelines\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22682,"versionId":15,"title":"June 2020","type":2,"subType":"0","childSubType":"","date":"6/23/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-june20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Intravenous Anesthetics for Off-Label Indications\u003c/li\u003e\n\u003cli\u003eSeparate Policy Established for Biochemical Markers of Bone Remodeling\u003c/li\u003e\n\u003cli\u003eUpdated Policy Format for Assisted Reproductive Technology\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22382,"versionId":15,"title":"May 2020","type":2,"subType":"0","childSubType":"","date":"5/22/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-may20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for IL-1 and IL-1b Blockers\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Eptinezumab-jjmr (Vyepti)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22238,"versionId":15,"title":"April 2020","type":2,"subType":"0","childSubType":"","date":"4/20/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-apr20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Established for Coronavirus (COVID-19) Testing\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Givosiran (Givlaari)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Luspatercept (Reblozyl)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":22011,"versionId":15,"title":"March 2020","type":2,"subType":"0","childSubType":"","date":"3/30/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-mar20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Enfortumab Vedotin-ejfv (Padcev)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Leadless Cardiac Pacemakers\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCriteria Revised/Facility Added for Transcatheter Aortic Valve Replacement\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21799,"versionId":15,"title":"February 2020","type":2,"subType":"0","childSubType":"","date":"2/23/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-feb20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-20.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Intravitreal Injections\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Testosterone Androgens\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Crizanlizumab-tmca (Adakveo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21667,"versionId":15,"title":"January 2020","type":2,"subType":"0","childSubType":"","date":"1/27/2020","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-jan20.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-20.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eClinical Guidelines Established for V-Go, Disposable Insulin Delivery Device; New Criteria Added for External Insulin Pumps\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Gonadotropin Releasing Hormones Analogs\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21441,"versionId":15,"title":"December 2019","type":2,"subType":"0","childSubType":"","date":"12/17/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-dec19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-19.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Golimumab (Simponi, Simponi Aria)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Ustekinumab (Stelara)\u003c/li\u003e\n\u003cli\u003eFacility added for Prophylactic Mastectomy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":21104,"versionId":15,"title":"November 2019","type":2,"subType":"0","childSubType":"","date":"11/20/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-nov19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-19.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Levoleucovorin (Khapzory)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Elotuzumab (Empliciti)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20889,"versionId":15,"title":"October 2019","type":2,"subType":"0","childSubType":"","date":"10/28/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-oct19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-19.pdf","urlText":"Read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Fluocinolone Acetonide (Yutiq)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Obesity Policy\u003c/li\u003e\n\u003cli\u003eFacility added to Lung and Lobar Lung Transplantation\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20603,"versionId":15,"title":"September 2019","type":2,"subType":"0","childSubType":"","date":"9/20/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-sept19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Daratumumab (Darzalex)\u003c/li\u003e\n\u003cli\u003eFacility Added to Dental Services\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20466,"versionId":15,"title":"August 2019","type":2,"subType":"0","childSubType":"","date":"8/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-aug19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-aug-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eClinical Guidelines Established for Polatuzumab Vedotin-piiq (Polivy)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Intra-Articular Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCoverage Criteria for Treatment of Hyperhidrosis\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":20315,"versionId":15,"title":"July 2019","type":2,"subType":"0","childSubType":"","date":"7/25/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-july19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eInjectable Drugs Added to Site of Care\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Romosozumab-aqqg (Evenity)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Foot Orthotics for Conditions Other than Diabetes\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Brexanolone (Zulresso)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19793,"versionId":15,"title":"June 2019","type":2,"subType":"0","childSubType":"","date":"6/24/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-june19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Trastuzumab (Herceptin)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Bevacizumab (Avastin)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Updated for Preoperative Photographs\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19710,"versionId":15,"title":"May 2019","type":2,"subType":"0","childSubType":"","date":"5/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-may19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Tildrakizumab (Ilumya)\u003c/li\u003e\n\u003cli\u003eClinical Guidelines Established for Calcitonin Gene-Related Peptide (CGRP) Inhibitors\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19617,"versionId":15,"title":"April 2019","type":2,"subType":"0","childSubType":"","date":"4/29/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-apr19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Hemophilia Treatment Clotting Factors/Coagulant Blood Products\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Bevacizumab-awwb (Mvasi)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised/Facility added for Extracorporeal Membrane Oxygenation (ECMO)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19490,"versionId":15,"title":"March 2019","type":2,"subType":"0","childSubType":"","date":"3/22/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-mar19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Revised for Granulocyte Colony Stimulating Factors (G-CSF)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Rituximab-abbs (Truxima)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Foot Orthotics for Conditions Other than Diabetes\u003c/li\u003e\n\u003cli\u003e\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19287,"versionId":15,"title":"February 2019","type":2,"subType":"0","childSubType":"","date":"2/25/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-feb19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eReminder: Coverage Criteria for Alpha1-Proteinase Inhibitor Infusions\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Revised for Ocrelizumab (Ocrevus)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Reinstated for Donor Leukocyte Infusion for Hematologic Malignancies that\u0026nbsp;Relapse after Allogeneic Cell Transplant\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":19227,"versionId":15,"title":"January 2019","type":2,"subType":"0","childSubType":"","date":"1/28/2019","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-jan19.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-19.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Developed for Eustachian Tube Balloon Dilation\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17791,"versionId":15,"title":"December 2018","type":2,"subType":"0","childSubType":"","date":"12/20/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-dec18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Developed for Patisiran (Onpattro)\u003c/li\u003e\n\u003cli\u003eREMINDER: Musculoskeletal and Pain Management Program Update\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17648,"versionId":15,"title":"November 2018","type":2,"subType":"0","childSubType":"","date":"11/26/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-nov18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Histone Deacetylase (HDAC) Inhibitors\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Mogamulizumab-kpkc (Poteligeo)\u003c/li\u003e\n\u003cli\u003ePolymerized Sucralfate Malate Paste (ProThelial) Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eREMINDER: Molecular and Genomic Testing\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17553,"versionId":15,"title":"October 2018","type":2,"subType":"0","childSubType":"","date":"10/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-oct18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eNew Policy Established for Site of Care for Certain Injectable Drugs\u003c/li\u003e\n\u003cli\u003eRevised Coverage Guidelines for Thermography (Thermogram)\u003c/li\u003e\n\u003cli\u003eREMINDER: Radiology and Cardiac Imaging Program\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17383,"versionId":15,"title":"September 2018","type":2,"subType":"0","childSubType":"","date":"9/24/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-sept18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Established for Heplisav\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Autonomic Nervous System Function Testing\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Treatment of the Prostate\u003c/li\u003e\n\u003cli\u003eRevised Coverage Criteria for Gender Reassignment Surgery\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17262,"versionId":15,"title":"August 2018","type":2,"subType":"0","childSubType":"","date":"8/27/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-aug18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-aug-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Guidelines Updated for Hemophilia Treatment\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Nusinersen (Spinraza)\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Developed for Vestronidase Alpha (Mepsevii)\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17143,"versionId":15,"title":"July 2018","type":2,"subType":"0","childSubType":"","date":"7/30/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-july18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eCoverage Guidelines Established for Ibalizumab-uiyk (Trogarzo)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Wheelchairs and Wheelchair Accessories\u0026nbsp;\u003c/li\u003e\n\u003cli\u003eChemotherapy Injectable Drug Policies Revised to Include Delaware HB 120 Mandate\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":17000,"versionId":15,"title":"June 2018","type":2,"subType":"0","childSubType":"","date":"6/25/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-june18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Guidelines Revised for Programmed Death Receptor (PD-1)/Programmed Death Ligand (PDL1)\u0026nbsp;Blocking Antibodies\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eRecommendations Established for Evidence-Based Practice\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNew Coverage Criteria Established for Inhaled Nitric Oxide\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":16898,"versionId":15,"title":"May 2018","type":2,"subType":"0","childSubType":"","date":"5/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-may18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Guidelines Revised for Azacitidine (Vidaza)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Guidelines Revised for Fulvestrant (Faslodex)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePlace of Service Revised for Total Hip and Total Knee Arthroplasty\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":16812,"versionId":15,"title":"April 2018","type":2,"subType":"0","childSubType":"","date":"4/30/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-apr18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eClinical Guidelines Revised for Bortezomib (Velcade)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Revised for Pneumatic Compression Devices\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNew Policy: Radiation Treatment with Lutathera\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":15269,"versionId":15,"title":"March 2018","type":2,"subType":"0","childSubType":"","date":"3/22/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-mar18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Established for Infliximab-qbtx (Ixifi)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Criteria Revised for Cetuximab (Erbitux)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverage Position Established for GI Effects Comprehensive Stool Profile\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAnd More\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":14287,"versionId":15,"title":"February 2018","type":2,"subType":"0","childSubType":"","date":"2/26/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-feb18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Dopamine Transporter Imaging With Single-Photon Emission Computed Tomography (DaT-SPECT/DaTscan)\u003c/li\u003e\n\u003cli\u003eCoverage for Occupational Therapy\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea for Adults - RETRACTED\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":14233,"versionId":15,"title":"January 2018","type":2,"subType":"0","childSubType":"","date":"1/29/2018","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-jan18.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-18.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Alpha1-Proteinase Inhibitor Infusions\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Chimeric Antigen Receptor T-Cell Therapy\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":13357,"versionId":15,"title":"December 2017","type":2,"subType":"0","childSubType":"","date":"12/22/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-12-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-17.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea for Adults\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Criteria Revised for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Transcatheter Aortic Valve Replacement (TAVR)\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":11142,"versionId":15,"title":"November 2017","type":2,"subType":"0","childSubType":"","date":"11/27/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-11-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-17.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003eNew Coverage Criteria Established for Pralatrexate (Folotyn)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Revised for Artifical Intervertebral Disc Replacement\u003c/li\u003e\n\u003cli\u003eCriteria Established for the Use of Amniotic Membrane Products and Amniotic Fluid to Treat Diabetic Ulcerts and Ophthalmic Conditions\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":9117,"versionId":15,"title":"October 2017","type":2,"subType":"0","childSubType":"","date":"10/30/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-10-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-17.pdf","urlText":"read","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCriteria Updated for Blinatumomab (Blincyto)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNew Policy: Medication Assisted Treatment (MAT) for Opioid Use Disorder: Methadone\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eREMINDER: Molecular and Genomic Testing\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eRadiology Management Program Update\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":7716,"versionId":15,"title":"September 2017","type":2,"subType":"0","childSubType":"","date":"9/25/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-09-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-17.pdf","urlText":"view medical policy update","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Golimumab (Simponi, Simponi Aria)\u003c/li\u003e\n\u003cli\u003eChange in Policy Position for In Vitro Chemoresistance and Chemosensitivity Assays\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Electromyography (EMG)\u003c/li\u003e\n\u003cli\u003eAnd More\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":6849,"versionId":15,"title":"August 2017","type":2,"subType":"0","childSubType":"","date":"8/28/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-08-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-aug-17.pdf","urlText":"view medical policy update","description":"\u003cul\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Confocal Laser Endomicroscopy\u003c/li\u003e\n\u003cli\u003eNew Policy Established for Lower Limb Prostheses\u003c/li\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Radiofrequency Ablation of Peripheral Nerves to Treat Chronic Knee Pain\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":4535,"versionId":15,"title":"July 2017","type":2,"subType":"0","childSubType":"","date":"7/26/2017","endDate":null,"additionalDate":null,"imageUrl":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-07-2017.gif","url":"https://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-17.pdf","urlText":"view medical policy update","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Changes for Paclitaxel, albumin-bound, Abraxane\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Laboratory Testing for Novel Influenza A (H1N1)\u003c/li\u003e\n\u003cli\u003eCriteria Updated for Acute Graft Versus Host Disease\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":3645,"versionId":15,"title":"June 2017","type":2,"subType":"0","childSubType":"","date":"6/23/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-06-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-17.pdf","urlText":"VIEW MEDICAL POLICY UPDATE","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Eculizumab\u003c/li\u003e\n\u003cli\u003eCoverage for Quadrivalent (RIV4) Influenza Virus Vaccine\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Bone Morphogentic Protein\u003c/li\u003e\n\u003cli\u003eAnd More!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":2595,"versionId":15,"title":"May 2017","type":2,"subType":"0","childSubType":"","date":"5/26/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-05-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-17.pdf","urlText":"VIEW MEDICAL POLICY UPDATE","description":"\u003cul\u003e\n\u003cli\u003eQuantity Limits for Breast Prosthesis and Mastectomy Bras\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Stereotactic Body Radiation Therapy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":589,"versionId":15,"title":"April 2017","type":2,"subType":"0","childSubType":"","date":"4/24/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-04-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-17.pdf","urlText":"VIEW MEDICAL POLICY UPDATE","description":"\u003cul\u003e\n\u003cli\u003eNew Coverage Position for Naltrexone Implant (or Pellets) for Treatment of Alcohol and Opioid Dependence\u003c/li\u003e\n\u003cli\u003eNew Coverage Position for Buprenorphine Implant for Treatment of Opioid Dependence\u003c/li\u003e\n\u003cli\u003eNew Policy Established for Ultra-Rapid Detoxification\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":false,"archive":false,"liveStatus":2},{"id":523,"versionId":15,"title":"March 2017","type":2,"subType":"0","childSubType":"","date":"3/1/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-03-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-17.pdf","urlText":"VIEW MEDICAL POLICY UPDATE","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Ipilimumab (Yervoy)\u003c/li\u003e\n\u003cli\u003eFacility Criteria Applied to Ilizarov Bone Lengthening\u003c/li\u003e\n\u003cli\u003eNew Policy - Coverage Criteria Established for Fibrin Sealants\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":353,"versionId":15,"title":"February 2017","type":2,"subType":"0","childSubType":"","date":"2/1/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-02-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-17.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eNew Policy Established for Intracellular Micronutrient Testing Panel\u003c/li\u003e\n\u003cli\u003eNew Coverage Position for Upper Gastrointestinal Endoscopy\u003c/li\u003e\n\u003cli\u003eNew Clinical Criteria for Air Ambulance Services Policy\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":4,"versionId":15,"title":"January 2017","type":2,"subType":"0","childSubType":"","date":"1/1/2017","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-01-2017.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-17.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\r\n\u003cli\u003eCriteria Revised for Bendamustine (Treanda) and Coverage Criteria Added for Bendamustine (Bendeka)\u003c/li\u003e\r\n\u003cli\u003eCriteria Revised for Mepolizumab (NUCALA) and Coverage Criteria Added for Reslizumab (CINQAIR)\u003c/li\u003e\r\n\u003cli\u003eCoverage for Removal of Skin Lesions\u003c/li\u003e\r\n\u003cli\u003eAnd more!\u003c/li\u003e\r\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":5,"versionId":15,"title":"December 2016","type":2,"subType":"0","childSubType":"","date":"12/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-12-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\r\n\u003cli\u003eAbobotulinumtoxinA (DYSPORT) Now Covered for Lower Limb Spasticity in Pediatric Patients 2 Years of Age and Older\u003c/li\u003e\r\n\u003cli\u003eExondys 51 Considered Experimental/Investigational\u003c/li\u003e\r\n\u003cli\u003eNew Coverage Criteria for Omalizumab (Xolair)\u003c/li\u003e\r\n\u003cli\u003eREMINDER: Molecular and Genomic Testing\u003c/li\u003e\r\n\u003cli\u003eNew Coverage Criteria for Radiofrequency Facet Denervation\u003c/li\u003e\r\n\u003cli\u003eAnd more!\u003c/li\u003e\r\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":6,"versionId":15,"title":"November 2016","type":2,"subType":"0","childSubType":"","date":"11/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-11-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\r\n\u003cli\u003eNew Coverage Position for Ramucirumab (Cyramza)\u003c/li\u003e\r\n\u003cli\u003eRevised Criteria for Gender Reassignment Surgery\u003c/li\u003e\r\n\u003cli\u003eCriteria Revised for Hematopoietic Stem Cell Transplantation for AL Amyloidosis (Primary Systemic Amyloidosis)\u003c/li\u003e\r\n\u003cli\u003eAnd more!\u003c/li\u003e\r\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":524,"versionId":15,"title":"October 2016","type":2,"subType":"0","childSubType":"","date":"10/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-10-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-oct-16.pdf","urlText":"VIEW MEDICAL POLICY UPDATE","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Ziv-aflibercept (Zaltrap)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Intraoperative Neurophysiologic Monitoring; Facility Application Added \u0026ndash; RETRACTED\u003c/li\u003e\n\u003cli\u003eClinical Criteria Developed for the Nucleus Hybrid L24 Cochlear Implant System\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":526,"versionId":15,"title":"September 2016","type":2,"subType":"0","childSubType":"","date":"9/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-09-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eManipulation Services\u003c/li\u003e\n\u003cli\u003eNoncontact Ultrasound Therapy for Chronic Wound Management is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Diagnosis and Treatment of Obstructive Sleep Apnea in Adults\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":527,"versionId":15,"title":"August 2016","type":2,"subType":"0","childSubType":"","date":"8/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-08-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-au-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eCorrection: Coverage Criteria Revised for Trastuzumab (Herceptin)\u003c/li\u003e\n\u003cli\u003eClinical Criteria Has Been Created for the Dohlman Doane Boston KPro (Boston KPro) Artificial Cornea\u003c/li\u003e\n\u003cli\u003eHF10 Spinal Cord Stimulation Coverage Position Changing Oct. 31, 2016\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":528,"versionId":15,"title":"July 2016","type":2,"subType":"0","childSubType":"","date":"7/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-07-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eBurn Criteria Added to Non-Custom/Custom-Made Gradient Compression Garments/Stockings/Sleeves\u003c/li\u003e\n\u003cli\u003eClinical Criteria Revised for Hyaluronan Injections for Osteoarthritis of the Knee\u003c/li\u003e\n\u003cli\u003eAlcohol Injection into Interdigital Neuromas for the Treatment of Peripheral Nerve Pain Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":529,"versionId":15,"title":"June 2016","type":2,"subType":"0","childSubType":"","date":"6/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-06-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eRevised Criteria for Home Apnea Monitors\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Hybrid Cardiac Ablation Procedure\u003c/li\u003e\n\u003cli\u003eRevised Criteria and Title Change for Endovascular Aneurysm Repair\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":530,"versionId":15,"title":"May 2016","type":2,"subType":"0","childSubType":"","date":"5/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-05-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for the Use of PAP Devices\u003c/li\u003e\n\u003cli\u003eRevised Criteria for Gemcitabine HCl (Gemzar)\u003c/li\u003e\n\u003cli\u003eCyanoacrylate Adhesive (e.g., VenaSeal Closure System) is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":531,"versionId":15,"title":"April 2016","type":2,"subType":"0","childSubType":"","date":"4/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-04-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Ultrasound Use in the Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eDocetaxel (Taxotere) No Longer Covered for the Treatment of Penile Cancer\u003c/li\u003e\n\u003cli\u003eClinical Criteria Revised for the Testing for Lyme Disease\u003c/li\u003e\n\u003cli\u003eProducts Approved for Treatment of Diabetic Lower Extremity Ulcers\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":532,"versionId":15,"title":"March 2016","type":2,"subType":"0","childSubType":"","date":"3/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-03-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eUrolift for Benign Prostatic Hypertrophy to be Considered Medically Necessary When Coverage Criteria Are Met\u003c/li\u003e\n\u003cli\u003eMedically Necessary Modifiers Added to Coverage Requirements for Routine Foot Care and Debridement of Mycotic/Hypertrophic Nails\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Coverage of Mastectomy and Reconstructive Surgery\u003c/li\u003e\n\u003cli\u003eHCPCS Quarterly Coding Updates\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":533,"versionId":15,"title":"February 2016","type":2,"subType":"0","childSubType":"","date":"2/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-02-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Multi-gene Expression Assay for Predicting Recurrence in Colon Cancer\u003c/li\u003e\n\u003cli\u003eUpdated Criteria for Cardiac Rehabilitation Program, Phase II Outpatient\u003c/li\u003e\n\u003cli\u003eNew Criteria Established for Coverage of Magnetic Resonance Imaging (MRI) of the Breast\u003c/li\u003e\n\u003cli\u003eSurgical Treatment of Lymphedema Added to Medical Policy Y-11, Treatments for Lymphedema\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":534,"versionId":15,"title":"January 2016","type":2,"subType":"0","childSubType":"","date":"1/1/2016","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/2xmpu-01-2016.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-16.pdf","urlText":"View Medical Policy Update","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Human Growth Hormone\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Immunotherapy for Prostate Cancer\u003c/li\u003e\n\u003cli\u003ePolicy Criteria Revised for Genetic Testing for Hereditary Breast and/or Ovarian Cancer\u003c/li\u003e\n\u003cli\u003eTimed Therapy Codes\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":572,"versionId":15,"title":"December 2015","type":2,"subType":"0","childSubType":"","date":"12/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-15.pdf","urlText":"VIEW","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Outpatient Pulmonary Rehabilitation\u003c/li\u003e\n\u003cli\u003eNew Policy on PCSK9 Inhibitors\u003c/li\u003e\n\u003cli\u003eSurgical Treatment of Lymphedema Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":573,"versionId":15,"title":"November 2015","type":2,"subType":"0","childSubType":"","date":"11/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-nov-15.pdf","urlText":"VIEW","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Revised for Immune Globulin Therapy\u003c/li\u003e\n\u003cli\u003eClinical Criteria Established for Coverage of Testosterone Androgens\u003c/li\u003e\n\u003cli\u003eCoverage Criteria for Cardiac Ablation Procedures Have Changed\u003c/li\u003e\n\u003cli\u003eBraces and Supports Guidelines Added\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":574,"versionId":15,"title":"October 2015","type":2,"subType":"0","childSubType":"","date":"10/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-dec-15.pdf","urlText":"VIEW","description":"\u003cul\u003e\n\u003cli\u003eDigital Breast Tomosynthesis Coverage Update\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Genetic Testing\u003c/li\u003e\n\u003cli\u003eMeniscal Allograft Transplantation Criteria Revised\u003c/li\u003e\n\u003cli\u003eUnderstanding When to Use New Patient vs Established Patient Evaluation and Management Codes\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":575,"versionId":15,"title":"September 2015","type":2,"subType":"0","childSubType":"","date":"9/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-sept-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eHCPCS Quarterly Coding Updates\u003c/li\u003e\n\u003cli\u003eHighmark Specialty Subcommittee Opportunity\u003c/li\u003e\n\u003cli\u003eObstetrical Ultrasound Criteria Revised\u003c/li\u003e\n\u003cli\u003eDiagnosis and Treatment of Sacroiliac Joint Pain Coverage Criteria Revised\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":576,"versionId":15,"title":"August 2015","type":2,"subType":"0","childSubType":"","date":"8/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-aug-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eConservative Therapy First-Line Treatment for Stress Urinary Incontinence\u003c/li\u003e\n\u003cli\u003eElectrical Nerve Stimulation Updated\u003c/li\u003e\n\u003cli\u003eInhalation Products for the Management of Cystic Fibrosis\u003c/li\u003e\n\u003cli\u003eOVA1 Assay for Ovarian Cancer Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":577,"versionId":15,"title":"July 2015","type":2,"subType":"0","childSubType":"","date":"7/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-july-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eQuantity Level Limits for Diabetic Test Strips and Lancets are Increased\u003c/li\u003e\n\u003cli\u003eElectrical Nerve Stimulation Updated\u003c/li\u003e\n\u003cli\u003eEmergency Room, Emergency Medical Care/Urgent Care, and Emergency Accident Care Policy Delayed\u003c/li\u003e\n\u003cli\u003eUltrasound Guidance Limitation\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":578,"versionId":15,"title":"June 2015","type":2,"subType":"0","childSubType":"","date":"6/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-june-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eObesity Criteria Revised\u003c/li\u003e\n\u003cli\u003eSupervision of Preparation and Provision of Single or Multiple Antigens Clarified\u003c/li\u003e\n\u003cli\u003eCriteria Updated for Intra-articular Hyaluronan Injections\u003c/li\u003e\n\u003cli\u003eDosing Limits for Stelara to be Enforced for Prior Authorization Requests as of August 3, 2015\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":579,"versionId":15,"title":"May 2015","type":2,"subType":"0","childSubType":"","date":"5/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-may-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eAdditional Tests Added to Medical Policy L-34, Genetic Testing\u003c/li\u003e\n\u003cli\u003eNew Policy for Selected Tests for Rheumatic Disease\u003c/li\u003e\n\u003cli\u003eOncotypeDX Gene Expression Assay for Prostate Cancer Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eNew Criteria for Non-Invasive Vascular Diagnostic Studies\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":580,"versionId":15,"title":"April 2015","type":2,"subType":"0","childSubType":"","date":"4/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-apr-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCriteria Revised for Passive Motion Machines\u003c/li\u003e\n\u003cli\u003eNew Medical Policy on Eculizumab (Soliris)\u003c/li\u003e\n\u003cli\u003eCologuard Multi-Target Stool Test is Considered Experimental/Investigational\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Laminectomy\u003c/li\u003e\n\u003cli\u003eAnd more! \u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":581,"versionId":15,"title":"March 2015","type":2,"subType":"0","childSubType":"","date":"3/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-mar-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eREMINDER: Sleep Studies\u003c/li\u003e\n\u003cli\u003eNew Criteria for Mastectomy and Reconstructive Surgery\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Surgical Treatment of Varicose Veins\u003c/li\u003e\n\u003cli\u003eNew Procedure Code and Modifiers for Reporting\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":582,"versionId":15,"title":"February 2015","type":2,"subType":"0","childSubType":"","date":"2/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-feb-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Repository Corticotropin Intramuscular Injection (H.P. Acthar Gel) Applicable to Both Facility and Professional\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Pharmacologic Treatment of Pulmonary Hypertension\u003c/li\u003e\n\u003cli\u003eAdditional Criteria Added for Testing and Treatment of Lyme Disease\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2},{"id":583,"versionId":15,"title":"January 2015","type":2,"subType":"0","childSubType":"","date":"1/1/2015","endDate":null,"additionalDate":null,"imageUrl":"http://content.highmarkprc.com/Files/NewsletterNotices/MPU/2xmpu-default.gif","url":"http://content.highmarkprc.com/Files/Region/hdebcbs/NewsletterNotices/MPU/mpu-jan-15.pdf","urlText":"view","description":"\u003cul\u003e\n\u003cli\u003eCoverage Criteria Established for Alemtuzumab (Lemtrada)\u003c/li\u003e\n\u003cli\u003eCriteria Revised for Electrical Nerve Stimulation\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Fulvestrant (Faslodex)\u003c/li\u003e\n\u003cli\u003eCoverage Criteria Established for Nivolumab (Opdivo)\u003c/li\u003e\n\u003cli\u003eAnd more!\u003c/li\u003e\n\u003c/ul\u003e","longDescription":null,"visible":true,"archive":false,"liveStatus":2}]